A notable trend favoring the Tr + RHT arm was seen in patients ( n = 39) who received five or more cycles, although this did not reach statistical significance (HR 0.60, 95% CI 0.30-1.18) ( Supplementary Figure S1 , available at https://doi.org/10.1016/j.esmoop.2026.106921 ).
← all excerpts
A randomized clinical study comparing trabectedin combined with regional hyperthermia with trabectedin in patients with advanced soft tissue sarcoma: HyperTET, a German Interdisciplinary Sarcoma Group trial.
1
—
—